LUDWIG, H., M.A. DIMOPOULOS, P. MOREAU, W.J. CHNG, H. GOLDSCHMIDT, Roman HÁJEK, T. FACON, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSINOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, A. PALUMBO, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S.B. FENG a D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2017, roč. 58, č. 10, s. 2501-2504. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2017.1298755. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1398977, author = {Ludwig, H. and Dimopoulos, M.A. and Moreau, P. and Chng, W.J. and Goldschmidt, H. and Hájek, Roman and Facon, T. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosinol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Palumbo, A. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S.B. and Joshua, D.}, article_location = {LONDON}, article_number = {10}, doi = {http://dx.doi.org/10.1080/10428194.2017.1298755}, keywords = {Carfilzomib; dexamethasone; bortezomib}, language = {eng}, issn = {1042-8194}, journal = {LEUKEMIA & LYMPHOMA}, title = {Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup}, url = {http://dx.doi.org/10.1080/10428194.2017.1298755}, volume = {58}, year = {2017} }
TY - JOUR ID - 1398977 AU - Ludwig, H. - Dimopoulos, M.A. - Moreau, P. - Chng, W.J. - Goldschmidt, H. - Hájek, Roman - Facon, T. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosinol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Palumbo, A. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S.B. - Joshua, D. PY - 2017 TI - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup JF - LEUKEMIA & LYMPHOMA VL - 58 IS - 10 SP - 2501-2504 EP - 2501-2504 PB - INFORMA HEALTHCARE SN - 10428194 KW - Carfilzomib KW - dexamethasone KW - bortezomib UR - http://dx.doi.org/10.1080/10428194.2017.1298755 L2 - http://dx.doi.org/10.1080/10428194.2017.1298755 N2 - Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. ER -
LUDWIG, H., M.A. DIMOPOULOS, P. MOREAU, W.J. CHNG, H. GOLDSCHMIDT, Roman HÁJEK, T. FACON, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSINOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, A. PALUMBO, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S.B. FENG a D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, roč.~58, č.~10, s.~2501-2504. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2017.1298755.
|